-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Sh7F8oXCzyTtqFvKgf3Ozvy+xLdWR/fbNYRLfPLjI5JtIGf/tXfVBXbY7jGwqiAX Ag5xlCpNuamRM1OQu2siSQ== 0001193125-10-258915.txt : 20101112 0001193125-10-258915.hdr.sgml : 20101111 20101112162428 ACCESSION NUMBER: 0001193125-10-258915 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101109 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20101112 DATE AS OF CHANGE: 20101112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORCHID CELLMARK INC CENTRAL INDEX KEY: 0001107216 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 223392819 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30267 FILM NUMBER: 101186972 BUSINESS ADDRESS: STREET 1: 4390 US ROUTE ONE CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6097502200 MAIL ADDRESS: STREET 1: 4390 US ROUTE ONE CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: ORCHID BIOSCIENCES INC DATE OF NAME CHANGE: 20000217 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2010

 

 

Orchid Cellmark Inc.

(Exact name of the registrant as specified in its charter)

 

 

 

Delaware   000-30267   22-3392819

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

4390 US Route One, Princeton, NJ 08540

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 750-2200

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At our Annual Meeting of Stockholders on November 9, 2010, our stockholders: (i) elected each of Eugene I. Davis and Stefan Loren as a Class I Director of the Company to serve a three-year term expiring in 2013 (Proposal 1); and (ii) ratified the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2010 (Proposal 2).

The following table sets forth information regarding the number of votes cast for, against or withheld, abstentions and broker non-votes, with respect to each matter presented at the meeting.

 

          For      Against      Withheld      Abstain      Broker
Non-Votes		  

Proposal 1

   

Eugene I. Davis

      11,105,856         N/A         6,496,841         N/A         6,517,939   
  

Stefan Loren

      17,350,440         N/A         252,257         N/A         6,517,939   

Proposal 2

   

Ratification of Grant Thornton LLP

      24,002,246         90,412         N/A         27,978         N/A   

In addition to Mr. Davis and Dr. Loren, the following directors continue to serve on the board of directors: Thomas A. Bologna, Nicole S. Williams, Bruce D. Dalziel and Dr. James M. Hart.

On November 9, 2010, the Board of Directors elected Mr. Davis as Chairman of the Board of Directors and appointed Mr. Davis to the following committees of the Board: Compensation Committee (together with Mr. Dalziel and Dr. Loren); and Nominating and Governance Committee (together with Dr. Hart and Ms. Williams). The Board of Directors appointed Dr. Loren to the following committees of the Board: Audit Committee (together with Mr. Dalziel and Ms. Williams); and Compensation Committee.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Orchid Cellmark Inc.
Date: November 12, 2010   By:  

/s/ William J. Thomas

  Name:   William J. Thomas
  Title:   Vice President and General Counsel
 -----END PRIVACY-ENHANCED MESSAGE-----